The mythbuster: Buying ‘innovative’ drugs is not the best use of NHS funds
By 
Steve Black2024-12-23T05:10:00
Rising drug costs strain NHS budgets, yet many new medicines deliver fewer health benefits than alternative interventions. A Lancet study underscores the need to reassess spending priorities and tackle inefficiencies in resource allocation for better patient outcomes, writes Steve Black
Register with hsj.co.uk to read the rest of this article
Critical stories remain free for registered users
Certain articles and Insight pieces remain paying-subscriber only content
As a registered user you will get access to:
- Daily News: an essential email round-up of all the latest news, comment and best practice
- Breaking news headlines delivered directly to your inbox
- Limited access to hsj.co.uk
Already registered to HSJ? Sign in now